Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Barclays

Barclays began coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note released on Monday, MarketBeat reports. The firm issued an underweight rating and a $25.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on CLDX. Citigroup lowered their target price on Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Canaccord Genuity Group restated a “buy” rating and issued a $62.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. Wells Fargo & Company lowered their target price on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright lowered their target price on Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $43.78.

Celldex Therapeutics Trading Up 1.3%

Shares of Celldex Therapeutics stock opened at $27.13 on Monday. The business’s fifty day simple moving average is $24.12 and its 200 day simple moving average is $21.55. The firm has a market capitalization of $1.80 billion, a P/E ratio of -9.01 and a beta of 1.33. Celldex Therapeutics has a 12 month low of $14.40 and a 12 month high of $31.66.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.01. The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. Analysts predict that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Several hedge funds have recently made changes to their positions in CLDX. Nisa Investment Advisors LLC grew its position in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 881 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Celldex Therapeutics by 6,665.9% in the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 2,933 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics in the second quarter valued at $125,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Celldex Therapeutics by 289.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,247 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 5,387 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.